Healthcare providers are recommending the consumption of non-vitamin K oral anticoagulants over commercially available medications such as Warfarin to reduce the incidence of atrial fibrillation in the stroke treatment market space. These efficacious oral anticoagulants are increasingly catching the attention of consumers and healthcare providers, as they effectively minimize the formation of clots in the blood. This is validated, as the revenue of anticoagulants amongst all drugs in the stroke treatment market is projected to hold the second-highest position, with a value of ~US$ 4.2 billion by 2027.
Oral anticoagulants are serving the convenience of stroke patients, as they can regularize any potential symptoms in home care settings. Thus, new oral anticoagulants are creating incremental opportunities for hospital, retail, and online pharmacies, as users can request for bulk orders at any given time. Healthcare companies in the stroke treatment market are developing improved formulations that make anticoagulants safer and help in reducing the risk of internal bleeding.
Healthcare companies in the stroke treatment market should increase their focus on drug development in the U.S. Favorable guidelines by health commissions and the well-established healthcare infrastructure of the U.S. are gaining the worldwide attention of stakeholders in the stroke treatment market.
Overall, North America is anticipated to maintain its lead in terms of market share and revenue during the forecast period, with a projected value of ~US$ 6.9 billion by 2027, in the stroke treatment market. Developments in the North American healthcare landscape are creating a ripple effect in the stroke treatment landscape of the U.S.
The introduction of new guidelines by health commissions in the U.S. involves speeding up the procedure of providing thrombolytic therapy to patients suffering from acute ischemic stroke. These guidelines are increasing the convenience of patients, and healthcare providers are gaining credibility in the global stroke treatment market scenario. Healthcare providers in the U.S are aiming to increase speed targets every year. Also, patients are being provided intravenous tissue plasminogen activator (tPA) drugs within minutes of their hospital arrival.
Tissue plasminogen activator (tPA) drugs accounted for the highest revenue in 2018, with a global value of ~US$ 3.4 billion in the stroke treatment market. Healthcare companies gain monopoly through the sales of tPA drugs, as these are the only therapeutic agents meant to treat patients with acute ischemic stroke that have been approved by health commissions across nations. However, delayed administration of tPA drugs in acute ischemic stroke patients can lead to health complications such as intracranial hemorrhage (ICH), hemorrhagic transformation (HT), and mortality. To overcome this challenge, companies are educating healthcare professionals regarding the administration of tPA drugs within 4.5 hours of a stroke onset. Also, manufacturers are developing new drug agents with improved formulations that help reduce the incidence of ischemia injuries in case of delayed tPA administration.
As such, healthcare companies in the stroke treatment market are increasing the availability of recombinant tissue plasminogen activators (rt-PA) to ease the health complications of acute ischemic stroke patients with their thrombolytic action. Positive clinical trials have compelled healthcare providers to prescribe rt-PA drugs in order to improve neuroplasticity in stroke patients.
Analysts’ Viewpoint
Manufacturers in the stroke treatment market are introducing reversal drug agents that minimize the incidence of life-threatening or uncontrolled bleeding in patients. Healthcare providers recommend the consumption of reversal agents in case oral anticoagulants are insufficient to treat stroke patients. Healthcare providers should increase their focus on non-pharmacological options such as percutaneous left atrial appendage occlusion for patients suffering from atrial fibrillation.
Though the market is expected to grow at a healthy CAGR of ~7%, manufacturers are challenged by the limitation of tPA drugs during delayed administration in patients. Hence, they should develop improved formulations of tPA that are efficacious, even after late administration of the drugs.
To contribute towards improving the quality of life in patients, companies should educate healthcare professionals to encourage patients for keeping a tab on weight management, as obesity leads to health complications such as sleep apnea, hypertension, hyperlipidemia, glucose intolerance, and the like.
Global Stroke Treatment Market – Segmentation
|
Type |
Ischemic Stroke Hemorrhagic Stroke |
|
Drug Class |
Tissue Plasminogen Activators (tPA) Anticoagulants Antiplatelets Anticonvulsants Others |
|
Distribution Channel |
Hospital Pharmacies Retail Pharmacies Online Pharmacies |
|
Region |
North America Europe Asia Pacific Latin America Middle East & Africa |
Stroke treatment market to reach a value of ~US$ 4.2 billion by 2027
Stroke treatment market is projected to grow at a CAGR of ~7% during 2019 - 2027
Stroke treatment market is driven by rise in the prevalence of stroke across the world
North America accounted for a major share of the global stroke treatment market
Key players in the global stroke treatment market include Bristol-Myers Squibb Company, Sanofi, Johnson & Johnson Services, Inc., Boehringer Ingelheim GmbH, F. Hoffmann-La Roche (Genentech)
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Stroke Treatment Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Stroke Treatment Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
5. Market Outlook
5.1. Key Industry Developments
5.2. Pipeline Analysis
5.3. Epidemiology Analysis
6. Global Stroke Treatment Market Value and Forecast, by Type
6.1. Introduction & Definition
6.2. Global Stroke Treatment Market Value Forecast, by Type, 2017–2027
6.2.1. Ischemic Stroke
6.2.2. Hemorrhagic Stroke
6.3. Global Stroke Treatment Market Attractiveness, by Type
7. Global Stroke Treatment Market Value and Forecast, by Drug Class
7.1. Introduction & Definition
7.2. Global Stroke Treatment Market Value Forecast, by Drug Class, 2017–2027
7.2.1. Tissue Plasminogen Activator (tPA)
7.2.2. Anticoagulants
7.2.3. Antiplatelets
7.2.4. Anticonvulsants
7.2.5. Others
7.3. Global Stroke Treatment Market Attractiveness, by Drug Class
8. Global Stroke Treatment Market Value and Forecast, by Distribution Channel
8.1. Introduction
8.2. Global Stroke Treatment Market Value Forecast, by Distribution Channel, 2017–2027
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
8.3. Global Stroke Treatment Market Attractiveness, by Distribution Channel
9. Global Stroke Treatment Market Value and Forecast, by Region
9.1. Introduction
9.2. Stroke Treatment Market Value Forecast, by Region, 2017–2027
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Stroke treatment Market Attractiveness, by Region
10. North America Stroke Treatment Market Analysis and Forecast
10.1. Introduction
10.2. North America Stroke Treatment Market Value Forecast, by Type, 2017–2027
10.2.1. Ischemic Stroke
10.2.2. Hemorrhagic Stroke
10.3. North America Stroke Treatment Market Value Forecast, by Drug Class, 2017–2027
10.3.1. Tissue Plasminogen Activator (tPA)
10.3.2. Anticoagulants
10.3.3. Antiplatelets
10.3.4. Anticonvulsants
10.3.5. Others
10.4. North America Stroke Treatment Market Value Forecast, by Distribution Channel, 2017–2027
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. North America Stroke Treatment Market Value Forecast, by Country/Sub-region, 2017–2027
10.5.1. U.S.
10.5.2. Canada
10.6. North America Stroke treatment Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Drug Class
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Stroke Treatment Market Analysis and Forecast
11.1. Introduction
11.2. Europe Stroke Treatment Market Value Forecast, by Type, 2017–2027
11.2.1. Ischemic Stroke
11.2.2. Hemorrhagic Stroke
11.3. Europe Stroke Treatment Market Value Forecast, by Drug Class, 2017–2027
11.3.1. Tissue Plasminogen Activator (tPA)
11.3.2. Anticoagulants
11.3.3. Antiplatelets
11.3.4. Anticonvulsants
11.3.5. Others
11.4. Europe Stroke Treatment Market Value Forecast, by Distribution Channel, 2017–2027
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Europe Stroke Treatment Market Value Forecast, by Country/Sub-region, 2017–2027
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Stroke treatment Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Drug Class
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Stroke Treatment Market Analysis and Forecast
12.1. Introduction
12.2. Asia Pacific Stroke Treatment Market Value Forecast, by Type, 2017–2027
12.2.1. Ischemic Stroke
12.2.2. Hemorrhagic Stroke
12.3. Asia Pacific Stroke Treatment Market Value Forecast, by Drug Class, 2017–2027
12.3.1. Tissue Plasminogen Activator (tPA)
12.3.2. Anticoagulants
12.3.3. Antiplatelets
12.3.4. Anticonvulsants
12.3.5. Others
12.4. Asia Pacific Stroke Treatment Market Value Forecast, by Distribution Channel, 2017–2027
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Asia Pacific Stroke Treatment Market Value Forecast, by Country/Sub-region, 2017–2027
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Stroke treatment Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Drug Class
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Stroke Treatment Market Analysis and Forecast
13.1. Introduction
13.2. Latin America Stroke Treatment Market Value Forecast, by Type, 2017–2027
13.2.1. Ischemic Stroke
13.2.2. Hemorrhagic Stroke
13.3. Latin America Stroke Treatment Market Value Forecast, by Drug Class, 2017–2027
13.3.1. Tissue Plasminogen Activator (tPA)
13.3.2. Anticoagulants
13.3.3. Antiplatelets
13.3.4. Anticonvulsants
13.3.5. Others
13.4. Latin America Stroke Treatment Market Value Forecast, by Distribution Channel, 2017–2027
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Latin America Stroke Treatment Market Value Forecast, by Country/Sub-region, 2017–2027
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Stroke treatment Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By Drug Class
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Stroke treatment Market Analysis and Forecast
14.1. Introduction
14.2. Middle East & Africa Stroke Treatment Market Value Forecast, by Type, 2017–2027
14.2.1. Ischemic Stroke
14.2.2. Hemorrhagic Stroke
14.3. Middle East & Africa Stroke Treatment Market Value Forecast, by Drug Class, 2017–2027
14.3.1. Tissue Plasminogen Activator (tPA)
14.3.2. Anticoagulants
14.3.3. Antiplatelets
14.3.4. Anticonvulsants
14.3.5. Others
14.4. Middle East & Africa Stroke Treatment Market Value Forecast, by Distribution Channel, 2017–2027
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Middle East & Africa Stroke Treatment Market Value Forecast, by Country/Sub-region, 2017–2027
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Stroke treatment Market Attractiveness Analysis
14.6.1. By Type
14.6.2. By Drug Class
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Global Stroke Treatment Market Position Analysis, by Company, 2018
15.2. Company Profiles
15.2.1. Bristol-Myers Squibb Company
15.2.1.1. Company Description
15.2.1.2. Business Overview
15.2.1.3. Financial Overview
15.2.1.4. Strategic Overview
15.2.1.5. SWOT Analysis
15.2.2. Boehringer Ingelheim GmbH
15.2.2.1. Company Description
15.2.2.2. Business Overview
15.2.2.3. Financial Overview
15.2.2.4. Strategic Overview
15.2.2.5. SWOT Analysis
15.2.3. Daiichi Sankyo Company, Limited
15.2.3.1. Company Description
15.2.3.2. Business Overview
15.2.3.3. Financial Overview
15.2.3.4. Strategic Overview
15.2.3.5. SWOT Analysis
15.2.4. F. Hoffmann-La Roche Ltd
15.2.4.1. Company Description
15.2.4.2. Business Overview
15.2.4.3. Financial Overview
15.2.4.4. Strategic Overview
15.2.4.5. SWOT Analysis
15.2.5. Johnson & Johnson Services, Inc.
15.2.5.1. Company Description
15.2.5.2. Business Overview
15.2.5.3. Financial Overview
15.2.5.4. Strategic Overview
15.2.5.5. SWOT Analysis
15.2.6. Sanofi
15.2.6.1. Company Description
15.2.6.2. Business Overview
15.2.6.3. Financial Overview
15.2.6.4. Strategic Overview
15.2.6.5. SWOT Analysis
15.2.7. Amgen, Inc.
15.2.7.1. Company Description
15.2.7.2. Business Overview
15.2.7.3. Financial Overview
15.2.7.4. Strategic Overview
15.2.7.5. SWOT Analysis
15.2.8. Biogen Inc.
15.2.8.1. Company Description
15.2.8.2. Business Overview
15.2.8.3. Financial Overview
15.2.8.4. Strategic Overview
15.2.8.5. SWOT Analysis
15.2.9. AstraZeneca
15.2.9.1. Company Description
15.2.9.2. Business Overview
15.2.9.3. Financial Overview
15.2.9.4. Strategic Overview
15.2.9.5. SWOT Analysis
List of Tables
Table 01: Pipeline Analysis for Stroke Treatment
Table 02: Global Stroke Treatment Market Value (US$ Mn) Forecast, by Type, 2017–2027
Table 03: Global Stroke Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 04: Global Stroke Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 05: Global Stroke Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 06: North America Stroke Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 07: North America Stroke Treatment Market Value (US$ Mn) Forecast, by Type, 2017?2027
Table 08: North America Stroke Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 09: North America Stroke Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017?2027
Table 10: Europe Stroke Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 11: Europe Stroke Treatment Market Value (US$ Mn) Forecast, by Type, 2017?2027
Table 12: Europe Stroke Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 13: Europe Stroke Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017?2027
Table 14: Asia Pacific Stroke Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 15: Asia Pacific Stroke Treatment Market Value (US$ Mn) Forecast, by Type, 2017?2027
Table 16: Asia Pacific Stroke Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 17: Asia Pacific Stroke Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017?2027
Table 18: Latin America Stroke Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 19: Latin America Stroke Treatment Market Value (US$ Mn) Forecast, by Type, 2017?2027
Table 20: Latin America Stroke Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 21: Latin America Stroke Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017?2027
Table 22: Middle East & Africa Stroke Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 23: Middle East & Africa Stroke Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017?2027
Table 24: Middle East & Africa Stroke Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 25: Middle East & Africa Stroke Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017?2027
List of Figures
Figure 01: Global Stroke Treatment Market Value (US$ Mn) and Distribution (%), by Region, 2019 and 2027
Figure 02: Global Stroke Treatment Market Value (US$ Mn) Forecast, 2017–2027
Figure 03: Global Stroke Treatment Market Value Share (%), by Type, 2018
Figure 04: Global Stroke Treatment Market Value Share (%), by Drug Class, 2018
Figure 05: Global Stroke Treatment Market Value Share (%), by Distribution Channel, 2018
Figure 06: Global Stroke Treatment Market Value Share (%), by Region, 2018
Figure 07: Stroke Treatment Market - Agreements, Collaborations, Partnerships & New Product Launch
Figure 08: Epidemiology of Stroke
Figure 09: Global Stroke Treatment Market Value Share (%), by Type, 2018 and 2027
Figure 10: Global Stroke Treatment Market Attractiveness, by Type, 2019–2027
Figure 11: Global Stroke Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Ischemic Stroke, 2017–2027
Figure 12: Global Stroke Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hemorrhagic Stroke, 2017–2027
Figure 13: Global Stroke Treatment Market Value Share (%), by Drug Class, 2018 and 2027
Figure 14: Global Stroke Treatment Market Attractiveness, by Drug Class, 2019–2027
Figure 15: Global Stroke Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Tissue Plasminogen Activator (tPA), 2017–2027
Figure 16: Global Stroke Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anticoagulants, 2017–2027
Figure 17: Global Stroke Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Antiplatelets, 2017–2027
Figure 18: Global Stroke Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anticonvulsants, 2017–2027
Figure 19: Global Stroke Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027
Figure 20: Global Stroke Treatment Market Value Share (%), by Distribution Channel, 2018 and 2027
Figure 21: Global Stroke Treatment Market Attractiveness, by Distribution Channel, 2019–2027
Figure 22: Global Stroke Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027
Figure 23: Global Stroke Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027
Figure 24: Global Stroke Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2017–2027
Figure 25: Global Stroke Treatment Market Value Share Analysis, by Region, 2018 and 2027
Figure 26: Global Stroke Treatment Market Attractiveness Analysis, by Region, 2019–2027
Figure 27: North America Stroke Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027
Figure 28: North America Stroke Treatment Market Value Share Analysis, by Country, 2018 and 2027
Figure 29: North America Stroke Treatment Market Attractiveness Analysis, by Country, 2019–2027
Figure 30: North America Stroke Treatment Market Value Share (%), by Type, 2018 and 2027
Figure 31: North America Stroke Treatment Market Attractiveness, by Type, 2019–2027
Figure 32: North America Stroke Treatment Market Value Share (%), by Drug Class, 2018 and 2027
Figure 33: North America Stroke Treatment Market Attractiveness, by Drug Class, 2019–2027
Figure 34: North America Stroke Treatment Market Value Share (%), by Distribution Channel, 2018 and 2027
Figure 35: North America Stroke Treatment Market Attractiveness, by Distribution Channel, 2019–2027
Figure 36: Europe Stroke Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027
Figure 37: Europe Stroke Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 38: Europe Stroke Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 39: Europe Stroke Treatment Market Value Share (%), by Type, 2018 and 2027
Figure 40: Europe Stroke Treatment Market Attractiveness, by Type, 2019–2027
Figure 41: Europe Stroke Treatment Market Value Share (%), by Drug Class, 2018 and 2027
Figure 42: Europe Stroke Treatment Market Attractiveness, by Drug Class, 2019–2027
Figure 43: Europe Stroke Treatment Market Value Share (%), by Distribution Channel, 2018 and 2027
Figure 44: Europe Stroke Treatment Market Attractiveness, by Distribution Channel, 2019–2027
Figure 45: Asia Pacific Stroke Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027
Figure 46: Asia Pacific Stroke Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 47: Asia Pacific Stroke Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 48: Asia Pacific Stroke Treatment Market Value Share (%), by Type, 2018 and 2027
Figure 49: Asia Pacific Stroke Treatment Market Attractiveness, by Type, 2019–2027
Figure 50: Asia Pacific Stroke Treatment Market Value Share (%), by Drug Class, 2018 and 2027
Figure 51: Asia Pacific Stroke Treatment Market Attractiveness, by Drug Class, 2019–2027
Figure 52: Asia Pacific Stroke Treatment Market Value Share (%), by Distribution Channel, 2018 and 2027
Figure 53: Asia Pacific Stroke Treatment Market Attractiveness, by Distribution Channel, 2019–2027
Figure 54: Latin America Stroke Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027
Figure 55: Latin America Stroke Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 56: Latin America Stroke Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 57: Latin America Stroke Treatment Market Value Share (%), by Type, 2018 and 2027
Figure 58: Latin America Stroke Treatment Market Attractiveness, by Type, 2019–2027
Figure 59: Latin America Stroke Treatment Market Value Share (%), by Drug Class, 2018 and 2027
Figure 60: Latin America Stroke Treatment Market Attractiveness, by Drug Class, 2019–2027
Figure 61: Latin America Stroke Treatment Market Value Share (%), by Distribution Channel, 2018 and 2027
Figure 62: Latin America Stroke Treatment Market Attractiveness, by Distribution Channel, 2019–2027
Figure 63: Middle East & Africa Stroke Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027
Figure 64: Middle East & Africa Stroke Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 65: Middle East & Africa Stroke Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 66: Middle East & Africa Stroke Treatment Market Value Share (%), by Type, 2018 and 2027
Figure 67: Middle East & Africa Stroke Treatment Market Attractiveness, by Type, 2019–2027
Figure 68: Middle East & Africa Stroke Treatment Market Value Share (%), by Drug Class, 2018 and 2027
Figure 69: Middle East & Africa Stroke Treatment Market Attractiveness, by Drug Class 2019–2027
Figure 70: Middle East & Africa Stroke Treatment Market Value Share (%), by Distribution Channel, 2018 and 2027
Figure 71: Middle East & Africa Stroke Treatment Market Attractiveness, by Distribution Channel, 2019–2027
Figure 72: Global Stroke Treatment Market Position Analysis, by Top Company Ranking, 2018
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Stroke Treatment Market
